| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | https://www.hindustanbiosciences.in/ | |
| Market Cap | 9.35 Cr. | |
| Enterprise Value(EV) | 11.94 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.00 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 38.75 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 0.67 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 13.54 | Calculated using Price: 9.12 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.03 Cr. | 10,250,800 Shares |
| FaceValue | 2 | |
| About Hindustan Bio Sciences Ltd. | ||
| Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society. | ||
| 1 Day |
|
+0.11% |
| 1 Week |
|
-6.25% |
| 1 Month |
|
-19.85% |
| 3 Month |
|
+64.35% |
| 6 Month |
|
+16.24% |
| 1 Year |
|
+136.25% |
| 2 Year |
|
+125.54% |
| 5 Year |
|
+817.48% |
| 10 Year |
|
+1501.69% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -19.21 | -35.60 | -10.74 | -71.30 | 5.22 | 3.67 | -52.96 | -49.49 | -5.28 | |
| Return on Capital Employed (%) | -16.78 | -30.17 | -8.37 | -49.03 | 2.68 | 2.40 | -23.70 | -16.66 | -1.10 | |
| Return on Assets (%) | -16.51 | -30.15 | -8.42 | -47.82 | 2.37 | 1.45 | -20.83 | -16.05 | -1.29 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 7 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Non Curr. Liab. | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Curr. Liab. | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 | 3 | 3 | |
| Non Curr. Assets | 7 | 5 | 5 | 3 | 4 | 3 | 2 | 2 | 2 | 2 | |
| Curr. Assets | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 | 3 | 3 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 0 | 1 | 1 | |
| Other Income | 0 | 0 | |||||||||
| Total Income | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 0 | 1 | 1 | |
| Total Expenditure | -2 | -1 | -1 | -3 | -3 | -2 | -2 | -1 | -1 | -1 | |
| PBIDT | -1 | 0 | 0 | -2 | 0 | 0 | -1 | -1 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Taxation | 0 | 0 | 0 | ||||||||
| Exceptional Items | -2 | ||||||||||
| PAT | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 | 0 | 0 | |
| Adjusted EPS | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | 0 | 0 | |
| Cash Fr. Inv. | 0 | 0 | |||||||||
| Cash Fr. Finan. | 1 | 0 | -1 | 0 | 0 | 2 | -1 | -1 | 0 | 0 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Thu, 23 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulation 30 (LODR) Newspaper Publication |
|
Thu, 23 Nov 2023
Board Meeting Intimation for Intimation Of Board Meeting For Considering The Notice Of EGM Intended For Regularization Of Additional Directors And Approval Of Appointment Of CFO Of The Company HINDUSTAN BIO SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/12/2023 inter alia to consider and approve Intimation of Board Meeting for considering the notice of EGM intended for regularization of additional directors and approval of appointment of CFO of the company |
|
Tue, 31 Oct 2023
Board Meeting Outcome for Outcome Of Board Meeting Outcome of board meeting |
| Fri, 01 Dec 2023 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Close Crossing Last Week Low
|
Close Crossing Last Month Low
|
Equities
M.F.
Sectors
StockEdge Social